Title | Author | Journal | Date | Link |
Non-viral vectors as beacons of hope for reducing genotoxic risks of gene therapy. | Nzila MM et al. | Nat Biomed Eng. | 5 January 2026 | |
Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. | Ianevski A et al. | Cancer Res. | 16 January 2026 | |
Delineating phenotypic heterogeneity in human regulatory T cells across developmental stages and therapeutic sources | Samikshya Santosh Nirmala et al. | Frontiers Immunology | 22 January 2026 | |
Anti-CD4 Antibody-modulated Transplants for GVHD Prevention in Hematopoietic Cell Transplantation - PubMed | Kristina Roth et al. | Blood | 26 January 2026 | |
Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe. | Ammar D et al. | Cytotherapy | 28 January 2026 | |
Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens. | Rieger L et al. | Blood | 29 January 2026 | |
Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma. | Riester Z et al. | Mol Ther. | 4 February 2026 | |
From byproduct to biotherapeutic: Comparative study of buffy coats and leukoreduction system chambers for NK cell-based immunotherapies. | Tietze M et al. | iScience. | 5 February 2026 | |
The ticking clock of relapse in T-cell lymphomas. | Jiang Q et al. | Blood. | 12 February 2026 | |
MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel. | Wiemers TC et al. | Leukemia | 17 February 2026 | |
Artificial intelligence-generated synthetic data for cancer research and clinical trials. | Eckardt JN et al. | Nat Rev Cancer. | 20 February 2026 | |
Extracorporeal photopheresis-New insights into an old procedure. | Seiffert S et al. | Transfus Med. | February 2026 | |
The sequence of 12 Gy total body irradiation and cyclophosphamide does not impact outcomes in AML patients receiving myeloablative allogeneic stem cell transplantation. | Franke GN et al. | Bone Marrow Transplant. | February 2026 | |
Epigenetic editing balances TCR suppression and persistence in CAR T cells. | Schönberg PY, Muñoz-Ovalle Á, Saleh HA, Crespo E, Kuhnert R, Michen S, Loureiro L, Temme A, Feldmann A, Buchholz F. | Mol Ther Adv. | 6 March 2026 | |
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma. | Rade M, Fandrei D, Kreuz M, Seiffert S, Grahnert A, Friedrich M, Wiemers T, Born P, Fischer L, Weidner H, Hofbauer LC, Baber R, Wang SY, Bach E, Hoffmann S, Scolnick J, Friedrich M, Keramati F, Brazda P, Sebestyen Z, Kuball J, Alb M, Scheller L, Hudecek M, Einsele H, Metzeler KH, Herling M, Herling CD, Jentzsch M, Franke GN, Boldt A, Köhl U, Platzbecker U, Vucinic V, Reiche K, Merz M. | Cancer Cell. | 9 March 2026 | |
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial. | Ruhnke L, Schliemann C, Mikesch JH, Stelljes M, Fransecky L, Steffen B, Kaufmann M, Burchert A, Rank A, Hanoun M, Höllein A, Kraus S, Schäfer-Eckart K, Hänel M, Haake A, Fiebig F, Kramer M, Zukunft S, Kunadt D, Middeke JM, Sockel K, Schetelig J, Platzbecker U, von Bonin M, Röhnert MA, Oelschlägel U, Wagenführ L, Thiede C, Herold S, Poitz D, Stölzel F, Baldus CD, Serve H, Wermke M, Bornhäuser M, Röllig C. | Lancet Haematol. | 13 March 2026 | |
Epigenetic editing balances TCR suppression and persistence in CAR T cells. | Schönberg PY, Muñoz-Ovalle Á, Saleh HA, Crespo E, Kuhnert R, Michen S, Loureiro L, Temme A, Feldmann A, Buchholz F. | Mol Ther Adv. | March 2026 | |
Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma. | Florey C, Velazquez GF, Lesan V, Krämer I, Kaiser F, Vehling-Kaiser U, Ossami-Saidy A, Huber H, Behringer A, Bentz M, Scholz JK, Gödel P, Schnetzke U, Vucinic V, Shorb E, Ghandili S, Kerkhoff A, Scheich S, Aydin S, Mayer K, Bacher U, Wille K, Glass B, Oellerich T, Ayuk F, Heidel F, Thurner L, Lutz M, Hänel M, Scholz CW, Tometten M, Pott C, Dreger P, Mougiakakos D, Dietrich S, Derenzini E, Chapuy B, Tresckow BV, Pabst T, Müller F, Lenz G. | Haematologica. | 2 April 2026 | |
Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma. | Schlierkamp-Voosen T, Barden M, Janning H, Kaljanac M, Harrer DC, Dreger C, Hammon K, Ertelt M, Schoeder CT, Halldórsdóttir HR, Rodriguez-Pardo C, Hadrup SR, Thomas S, Abken H. | Front Immunol. | 30 April 2026 | |
CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement. | Keitel V, Kreissl MC, Goetze T, Dröge C, Kuhn CK, Pham NN, Löffler D, Borie D, Schreiber J, Boettcher M, Hippe K, Pech M, Mikusko M, Köhl U, Walther D, Reiche K, Mougiakakos D. | J Hepatol. | April 2026 | |
Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis. | Velasco-de-Andrés M, Puerta-Alcalde P, Eitler J, Krutz L, Chumbita M, Español-Rego M, Català C, Carrillo-Serradell L, Planells-Romeo V, Aragón-Serrano L, Vergara A, Pérez-Valencia AI, Monzó-Gallo P, Gallardo-Pizarro A, Cibeira MT, Vlagea A, Caro JL, Palou E, Suárez-Lledó M, Soriano A, Calvo G, Urbano-Ispizua Á, Tonn T, Garcia-Vidal C, Lozano F. | Front Immunol. | 8 May 2026 | |
Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence. | Ferle M, Ader J, Wiemers T, Grieb N, Berneck B, Lindenmeyer A, Goldschmidt H, Mai EK, Bertsch U, Meyer HJ, Neumuth T, Kreuz M, Reiche K, Merz M. | NPJ Digit Med. | 11 May 2026 | |
Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma. | Rasche L, Krauth MT, Agis H, Renner C, Strassl I, Teipel R, Vučinić V, Weisel K, Willenbacher W, Raab MS. | Bone Marrow Transplant. | 13 May 2026 | |
INSTALLing recombinase-driven genome writing: Engineered single-stranded donors bypass innate immunity to enable large DNA integration. | Buchholz F. | Mol Cell. | 21 May 2026 | |
Fluorodeoxyglucose-PET/MRI-based response assessment following BCMA-directed CAR-T-cell therapy with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma. | Teipel R, Trautmann-Grill K, Kleditsch L, Epp K, Böttcher S, Röllig C, Weidner H, Gottschalk A, Glauche I, Brogsitter C, Platzek I, Apolle R, Bonin MV, Bornhäuser M, Winzer R, Miederer M. | Haematologica. | 21 May 2026 | |
Developing a pan cancer therapy based on DISE-inducing short RNAs. | Murmann AE, Ebadi M, Patel M, Ewe A, Barajas S, Xiao S, Ko MJ, Lee S, Cai W, Paudel B, Sun L, Bartom ET, Kocherginsky M, Liu Y, Kim DH, Aigner A, Peter ME. | Mol Ther Nucleic Acids. | 25 May 2026 | |
Artificial intelligence-generated synthetic data for cancer research and clinical trials. | Eckardt JN, Hahn W, Prelaj A, Bornhäuser M, Middeke JM, Kather JN. | Nat Rev Cancer. | 26 May 2026 | |
Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. | Krauß SM, Holloway T, Weigert A, Bischof L, Backhaus D, Brauer D, Ussmann J, Franke GN, Vučinić V, Platzbecker U, Schwind S, Jentzsch M, Metzeler KH. | Haematologica | 28 May 2026 | |
JUN Specifies the Local Differentiation and Maintenance of Pro-tumoral Monocyte-Derived Macrophages. | Delfini M, Baudoin E, Guo G, Francois M, Bebien M, Murgaski A, Bettacchioli E, Buferne M, Rastoin O, Belabed D, Moussard P, Mariot C, Baranska A, Verthuy C, Ruffinatto L, Mossadegh-Keller N, Vu Manh TP, Masse M, Soni A, Sieweke MH, Strauss LM, Pauladóttir Jensen M, Doktor TK, Etzerodt A, Auphan-Anezin N, Lawrence T. | Cancer Res. | 29 May 2026 | |
Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma. | Waldschmidt J, Fandrei D, Hecker JS, Meggendorfer M, Truger M, Reinhard F, Shibru B, Högner M, Gebauer A, Köppel M, Müller H, Jung J, Teschner D, Topp MS, Purcarea A, Vučinić V, Haferlach T, Bassermann F, Platzbecker U, Einsele H, Haferlach C, Kortüm KM, Metzeler KH, Merz M, Götze KS, Rasche L. | Leukemia. | May 2026 | |
Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells. | Krauß SM, Weibl K, Bach E, Brückner M, Weigert A, Tumewu T, Ruschpler E, Vogtmann G, Hoffmann S, Penack O, Janz M, Buhmann R, Henschler R, Bullinger L, Keller U, Schwind S, Merz M, Jentzsch M, Franke GN, Herling M, Platzbecker U, Metzeler KH, Vučinić V. | Bone Marrow Transplant. | 3 June 2026 | |
Novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneity. | Hübner J, Alsalkini M, McFleder R, Toppeta F, Wagner J, Liguori R, Grams B, Meyer-Hofmann M, Diener L, Monoranu CM, Hagemann C, Ferrazzi F, Ip CW, Ernestus RI, Einsele H, Hudecek M, Löhr M, Nerreter T, Nickl V. | J Immunother Cancer. | 3 June 2026 | |
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma. | Merz M, Jelinek T, Pabst T, Teipel R, Albici AM, von Tresckow B, Teichert M, Demel UM, Busse A, Wesener MC, Holderried TAW, Schmitz F, Rößiger FL, Müller F, Hoffmann M, Stölzel F, Tovar N, Baermann BN, Stork M, Jungova A, Minarik J, Radocha J, Spicka I, Pour L, Novak P, Slajpah K, Rener K, Keller U, Bohl S, Fandrei D, Born P, Vucinic V, Kröger N, Strassl I, Schub N, Hájek R, Sever M, Fernández de Larrea C, Gagelmann N. | Blood Cancer Discov. | 12 June 2026 | |
Next-generation LMP2A-targeting TCR recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies. | Bonifacius A, Mausberg P, Floegel F, Dragon AC, Tischer-Zimmermann S, Stoll S, Rahmati P, Spieler P, Lammoglia Cobo MF, Halenius A, Abken H, Blasczyk R, Nerreter T, Hudecek M, Schambach A, Hansmann L, Maecker-Kolhoff B, Eiz-Vesper B. | Mol Ther Oncol. | 21 June 2026 | |
Teclistamab interference with anti-BCMA chimeric antigen receptor T-cell detection by flow cytometry: duration and clinical implications. | Schadt J, von Bonin M, Oelschlägel U, Teipel R, Epp K, Saalfeld FC, Schulze F, Heuschkel S, Bornhäuser M, Röhnert MA. | Leukemia | 27 June 2026 | |
RNA sequencing indicates distinct platelet transcriptomic changes in immune thrombocytopenia. | Georgi JA, Hartwig M, Friedrich UA, Krause M, Dahl A, Altmann H, Stauch T, Middeke JM, Bornhäuser M, Bugert P, Thiede C, Trautmann-Grill K. | J Thromb Haemost. | 4 July 2026 | |
From monoclonal to polyfunctional immunotherapy: Reprogramming CAR T-cell therapy with oncolytic viruses in B cell malignancies. | Achim E, Ungerechts G, Tomuleasa C, Friedel S, Hudecek M, Cristea C, Tertis M, Einsele H. | Hemasphere | 7 July 2026 | |
A universally applicable toolbox for single-molecule quantification of chimeric antigen receptors using linker resolved dSTORM microscopy. | Michael J, Spieler P, Toppeta F, Gehrke L, Seifert N, Grams B, Seifert R, Einsele H, Hudecek M, Sauer M, Nerreter T. | Front Immunol | 15 July 2026 | |
Preclinical evaluation of a novel CD4 specific CAR NK cell therapy for T-cell malignancies | Ruppel KE, Lückemeier P, Scholz A, Stahringer A, Reiche K, Köhl U, Fricke S, Herling M, Schmiedel D | Cytotherapy | 28 July 2026 | |
Preclinical evaluation of a novel CD4 specific CAR NK cell therapy for T-cell malignancies | Ruppel KE, Lückemeier P, Scholz A, Stahringer A, Reiche K, Köhl U, Fricke S, Herling M, Schmiedel D | Cytotherapy | 28 July 2026 | |
In silico clinical trials of BiTE expression by oncolytic viruses reveal the impact of patient heterogeneity on dosage protocol. | Jenner AL, Araujo RP, Levi NL, Ungerechts G, Engeland CE, Heidbuechel JPW. | PLoS Comput Biol. | 30 July 2026 | |
Preclinical evaluation of a novel CD4 specific CAR NK cell therapy for T-cell malignancies. | Ruppel KE, Lückemeier P, Scholz A, Stahringer A, Reiche K, Köhl U, Fricke S, Herling M, Schmiedel D. | Cytotherapy | July 2026 | |
International Consensus Criteria for the Diagnosis, Treatment Initiation, and Response Assessment for T-LGL Leukemia. | Jonathan E. Brammer, Natali Pflug, Renato Zambello, Julia Almeida, Dima El-Sharkawi, Lubomir Sokol, David Feith, Zachary Braunstein, Miguel Ruiz, Till Braun, Tony Marchand, Satu Mustjoki, Carlos Bravo Perez, Monika Brüggemann, Pierluigi Porcu, Fumihiro Ishida, Jaroslaw P. Maciejewski, Marshall E. Kadin, Gianpietro Semenzato, Anton W. Langerak, Thierry Lamy, Thomas P Loughran, Marco Herling | Blood | 21 August 2026 | |
SLiTHER Enables Simple and Rapid Directed Evolution within Mammalian Cells. | Dai, Zixi and Ding, Li and Sandoval-Villegas, Nicolás and Sürün, Duran and Jelicic, Milica and Schmitt, Lukas Theo and Jain, Manavi and Buchholz, Frank | Cell Press | 31 August 2026 | |
Next-generation synthetic trials in hematology with generative artificial intelligence. | Eckardt JN, Bornhäuser M, Middeke JM. | Leukemia | 19 August 2026 | |
Novel PSCA-Targeting Adapter Molecules for Late-Stage RevCAR-T Cell Therapy in Prostate Cancer. | Arndt C, García de Andres I, Bergmann R, Mitwasi N, Neuber C, Soto KEG, Jones Cifuentes N, von Jutrzenka-Trzebiatowski A, Loureiro LR, Mathé D, Bachmann M, Feldmann A. | Int J Mol Sci. | August 2026 | |
The Evolution of FAP Targeted CAR T-Cell Therapy in Solid Tumors: From Immunotherapy to Immunotheranostic Applications. | Boutier H, Feldmann A, Bachmann M. | Int J Mol Sci. | 19 August 2026 | |
Accelerating Translation of NK Cell Therapies to the Clinic: A European Perspective. | Knapp LR, Fischer KS, Sosat J, Villena-Ossa JF, Kluge P, Schmiedel D, Kuball J, Dolstra H, Minguet S, Cornu TI, Cathomen T, Alici E, O'Dwyer M, Wels WS, Malmberg KJ, Romee R, Vivier E, Köhl U, Cerwenka A, Ullrich E. | Hum Gene Ther. | August 2026 | |
The German National Strategy for Gene- and Cell-Based Therapies: Generating Impact by Employing a Novel Multi-Stakeholder Approach. | Gallus C, Ayuk F, Beckhove P, Besser D, Bornhäuser M, Büning H, Cantz T, Conrad C, Eichmüller S, Gazlig T, Graessner H, Grüters-Kieslich A, Huber N, Hudecek M, Kurz T, Lamprecht B, Luger E, Protzer U, Schambach A, Schäfer R, Serrano P, Stegemann S, Stöckert I, von Kalle C, Weber J, Baum C. | Hum Gene Ther. | August 2026 |
|
Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells. | Krauß SM, Weibl K, Bach E, Brückner M, Weigert A, Tumewu T, Ruschpler E, Vogtmann G, Hoffmann S, Penack O, Janz M, Buhmann R, Henschler R, Bullinger L, Keller U, Schwind S, Merz M, Jentzsch M, Franke GN, Herling M, Platzbecker U, Metzeler KH, Vučinić V. | Bone Marrow Transplant. | August 2026 | |
Integrated transcriptomic and TCR profiling reveals local immune dysregulation of T cells in Gl aGvHD. | Goel M, Eugster A, Reinhardt S, Friedrich U, Dahl A, Wolters L, Lieth L, Steinberg Bains K, Schmitz M, Rachner TD, Poetsch AR, Kunadt D, Teipel R, Middeke JM, Sockel K, Stölzel F, von Bonin M, Schetelig J, Hartig A, Bornhäuser M, Bonifacio E, Link-Rachner CS. | Bone Marrow Transplant. | August 2026 | |
Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma. | Merz M, Jelinek T, Pabst T, Teipel R, Albici AM, von Tresckow B, Teichert M, Demel UM, Busse A, Wesener MC, Holderried TAW, Schmitz F, Rößiger FL, Müller F, Hoffmann M, Stölzel F, Tovar N, Baermann BN, Stork M, Jungova A, Minarik J, Radocha J, Spicka I, Pour L, Novak P, Slajpah K, Rener K, Keller U, Bohl S, Fandrei D, Born P, Vučinić V, Kröger N, Strassl I, Schub N, Hájek R, Sever M, Fernández de Larrea C, Gagelmann N. | Blood Cancer Discov. | 3 September 2026 | |
Prospecting the protein design landscape. | Riccabona JR, Stonig KT, Meiler J, Schoeder CT, Fernández-Quintero ML. | FEBS Lett. | 18 September 2026 | |
Preclinical evaluation of homodimeric FAPI target modules for UniCAR-mediated targeting of FAP expressing tumor and stromal cells. | Boutier H, Mattiussi S, Loureiro LR, Berndt N, Stammberger A, Jones-Cifuentes N, Hoffmann L, Verhulst E, Schmitz M, De Meester I, Battisti UM, Arndt C, Feldmann A, Roesch F, Herth MM, Bachmann M. | Oncoimmunology | 31 December 2026 |
